Structure-activity relationship studies of flavopiridol analogues.

@article{Murthi2000StructureactivityRS,
  title={Structure-activity relationship studies of flavopiridol analogues.},
  author={K. Murthi and M. Dubay and C. McClure and L. Brizuela and M. Boisclair and P. Worland and M. Mansuri and K. Pal},
  journal={Bioorganic \& medicinal chemistry letters},
  year={2000},
  volume={10 10},
  pages={
          1037-41
        }
}
Cyclin dependent kinases (CDKs) along with the complementary cyclins form key regulatory checkpoint controls on the cell cycle. Flavopiridol is a synthetic flavone that shows potent and selective cyclin-dependent kinase inhibitory activity. In this paper, we report modifications of the 3-hydroxy-1-methylpiperidinyl (D ring) of flavopiridol and their effect on CDK inhibitory activity. 
Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.
TLDR
The most active compound 13c resulting from a structure-activity relationship (SAR) study and in silico docking showed the best antiproliferative activity and was more efficient than the reference compound. Expand
Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation.
TLDR
A novel series of nitrogen-containing flavonoids 5a, 5b, 5e, and 5g showed potent CDK1/Cyclin B inhibitory activities in vitro against Bel-7402, PC-3, ECA-109, A-549, HL-60, and MCF-7 cancer cell lines. Expand
Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
TLDR
CDK1 selective thio- and oxoflavopiridol analogues inhibit the colony-forming ability of multiple human tumor cell lines and possess a unique antiproliferative profile in comparison to flavopirodol. Expand
Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Novel 2-benzylidene-benzofuran-3-ones were designed and synthesized to mimic flavopiridol, a well-established inhibitor of cyclin-dependent kinases (CDKs) which is currently undergoing clinicalExpand
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
TLDR
The synthesis of new analogues of Arcyriaflavin A in which one indole ring is replaced by an aryl or heteroaryl ring is described, and the potency, selectivity profile against other kinases, and structure-activity relationship (SAR) trends of this class of compounds are discussed. Expand
Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2
TLDR
The summary of the conformational characteristics and ligand binding mechanisms of CDK2 in the present work will improve the understanding of the molecular mechanisms regulating the bioactivities ofCDK2. Expand
Nitrogen-containing flavonoid analogues as CDK1/cyclin B inhibitors: synthesis, SAR analysis, and biological activity.
A series of nitrogen-containing flavonoid analogues were designed and synthesized by Mannich reaction, and screened for the inhibitory activities of cyclin-dependent kinases using a FRET-basedExpand
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.
TLDR
The present review mainly focuses on the structural requirement for anticancer potential of flavone derivatives targeting several key serine/threonine protein kinases, and may provide an opportunity to scientists of medicinal chemistry to design multi-functional Flavone derivatives for the treatment of cancer. Expand
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
TLDR
An updated list of compounds under clinical evaluation (phase I/II/III) and their mode of action as ATP- competitive inhibitors are discussed and tentative progress for forthcoming potential ATP non-competitive inhibitors and allosteric inhibitors is briefly described. Expand
A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
TLDR
A continuum solvent model is applied to study the interactions between cyclin-dependent kinase 2 (CDK2) and analogues of the clinically tested anticancer agent flavopiridol to gain insights into designing selective inhibitors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 12 REFERENCES
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
TLDR
The analysis of the position of this phenyl ring not only explains the great differences of kinase inhibition among the flavonoid inhibitors but also explains the specificity of L868276 to inhibit CDK2 and CDC2. Expand
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
TLDR
Several naturally occurring and synthetic analogues of PTK inhibitors were systematically evaluated in this review based on their structure-activity relationships and potential antitumor efficacy. Expand
Mammalian G1 cyclins.
  • G. Draetta
  • Biology, Medicine
  • Current opinion in cell biology
  • 1994
TLDR
Overexpression of cyclin D1 protein as a consequence of genetic rearrangements, and deletions or mutations of the p16INK4 gene have been demonstrated in a large variety of human cancers, including breast and esophageal carcinomas, lymphomas, bladder carcinoma, pancreatic adenocarcinoma and familial melanoma. Expand
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
TLDR
The maximum-tolerated dose (MTD) of infusional flavopiridol is 50 mg/m2/d x 3 with dose-limiting secretory diarrhea, based on chronic tolerability, which is the recommended phase II dose without ADP. Expand
The tumor suppressor protein p16INK4a.
  • M. Serrano
  • Biology, Medicine
  • Experimental cell research
  • 1997
The tumor suppressor protein p16INK4a (inhibitor of CDK4) is one of the most direct links between cell-cycle control and cancer. The p16INK4a gene is frequently inactivated in human tumors, andExpand
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.
TLDR
The findings suggest that L86-8275 is a candidate for further preclinical development, as well as a model for the synthesis of other flavonoids that might potently delay cell cycle progression to achieve inhibition of tumor growth. Expand
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
TLDR
Compounds 24, 26, and 27 were potent inhibitors of tubulin polymerization, with activity nearly comparable to that of the potent antimitotic natural products colchicine, podophyllotoxin, and combretastatin A-4. Expand
Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
TLDR
It is shown here that the melanoma associated p16 mutants are defective, as are some of the Ala mutants, and a region within the p16 molecule in which changes are likely to result in a defective protein is defined. Expand
Checkpoint Controls and Cancer; Kastan
  • 1997
Mammalian G1 cyclins
...
1
2
...